Delbios seeks to subcontract expert consulting services to support the strategic development and evaluation of nanoGLA through the preparation of a Target Product Profile (TPP) and an asset valuation analysis.
The objective is to define the desired clinical and product characteristics for nanoGLA, assess its positioning within the Fabry disease treatment landscape, and estimate the potential value of the asset based on development assumptions, market opportunity, and comparable benchmarks.
Proposals must be submitted by 1st april 2026, 23:59 CET to: info@delbios.com Subject: RFQ-BUS-001-2026 – Target Product Profile and Asset Valuation for nanoGLA
